Actinic Keratosis Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts

The Actinic Keratosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Actinic Keratosis pipeline products will significantly revolutionize the Actinic Keratosis market dynamics.

DelveInsight's "Actinic Keratosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Actinic Keratosis, historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Actinic Keratosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Actinic Keratosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Actinic Keratosis Market Forecast
https://www.delveinsight.com/sample-request/actinic-keratosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Actinic Keratosis Market Report:
• The Actinic Keratosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In November 2024, Vidac Pharma has secured €600,000 ($645,651) in additional funding to advance the clinical development of its two lead cancer candidates. Announced during the company's recent shareholder meeting, this funding from existing investors will allow Vidac to initiate a new Phase IIb trial for its lead candidate, VDA-1102 (tuvatexib) ointment. The hexokinase 2 inhibitor is being studied for its potential in treating advanced cases of actinic keratosis, a skin condition that may progress to cutaneous squamous cell carcinoma (SCC).
• Additionally, the launch of new therapies such as VDA-1102, SR-T100 Gel, and other innovative topical treatments is anticipated to enhance treatment outcomes and broaden market prospects.
• According to Chetty P et al., the prevalence of AK varies from 6-60%, depending on age, phototype and other predisposing risk factors (most notably immunosuppressed status, outdoor workers), and is increasing
• In a study conducted by Schaefer et al., it was found that the standardized prevalence of AK from dermatological examinations was 2.7%; the rate increased with age (11.5% in the group 60-70 years) and was higher for men (3.9%) than for women (1.5%)
• Key Actinic Keratosis Companies: Bausch Health Companies, Sandoz Pharmaceuticals, Athenex/ Almirall, Vidac Pharma, G&E Herbal Biotechnology, Vidac Pharma, DFB Soria, LLC, Coegin Pharma AB, and others
• Key Actinic Keratosis Therapies: ALDARA (imiquimod), SOLARAZE (diclofenac topical gel), KLISYRI (tirbanibulin/KX01/ KX2-391), VDA-1102, SR-T100 Gel, Tuvatexib (VDA-1102), SOR-007, AVX-001, and others
• The Actinic Keratosis epidemiology based on gender analyzed that Actinic Keratosis prevalence is higher among men than women of the same age. In Northern European and North American whites, AKs are uncommon before the age of 40 years

Actinic Keratosis Overview
Actinic keratosis (AK) is a common precancerous skin condition caused by prolonged sun exposure or tanning bed use. It appears as rough, scaly patches on the skin, often on sun-exposed areas like the face, ears, neck, scalp, chest, backs of hands, forearms, or lips. AK is typically red or pink but can also be brown, gray, or skin-colored. While most AK lesions do not develop into skin cancer, they can evolve into squamous cell carcinoma if left untreated. Treatment options include cryotherapy, topical medications, laser therapy, and other procedures aimed at removing or destroying the abnormal cells.

Get a Free sample for the Actinic Keratosis Market Report:
https://www.delveinsight.com/report-store/actinic-keratosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Actinic Keratosis Market
The dynamics of the Actinic Keratosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
"Increasing Prevalence of disease and growing consumer awareness, will fuel the Actinic Keratosis (AK) market"

Actinic Keratosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Actinic Keratosis Epidemiology Segmentation:
The Actinic Keratosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Actinic Keratosis
• Prevalent Cases of Actinic Keratosis by severity
• Gender-specific Prevalence of Actinic Keratosis
• Diagnosed Cases of Episodic and Chronic Actinic Keratosis

Download the report to understand which factors are driving Actinic Keratosis epidemiology trends @ Actinic Keratosis Epidemiological Insights
https://www.delveinsight.com/sample-request/actinic-keratosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Actinic Keratosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Actinic Keratosis market or expected to get launched during the study period. The analysis covers Actinic Keratosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Actinic Keratosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Actinic Keratosis Therapies and Key Companies
• ALDARA (imiquimod): Bausch Health Companies
• SOLARAZE (diclofenac topical gel): Sandoz Pharmaceuticals
• KLISYRI (tirbanibulin/KX01/ KX2-391): Athenex/ Almirall
• VDA-1102: Vidac Pharma
• SR-T100 Gel: G&E Herbal Biotechnology
• Tuvatexib (VDA-1102): Vidac Pharma
• SOR-007: DFB Soria, LLC
• AVX-001: Coegin Pharma AB

Actinic Keratosis Market Unmet Needs
• Challenges in diagnosis
• Development of novel therapies
• The High cost of treatment
• Limited or no awareness about the disease

Scope of the Actinic Keratosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Actinic Keratosis Companies: Bausch Health Companies, Sandoz Pharmaceuticals, Athenex/ Almirall, Vidac Pharma, G&E Herbal Biotechnology, Vidac Pharma, DFB Soria, LLC, Coegin Pharma AB, and others
• Key Actinic Keratosis Therapies: ALDARA (imiquimod), SOLARAZE (diclofenac topical gel), KLISYRI (tirbanibulin/KX01/ KX2-391), VDA-1102, SR-T100 Gel, Tuvatexib (VDA-1102), SOR-007, AVX-001, and others
• Actinic Keratosis Therapeutic Assessment: Actinic Keratosis current marketed and Actinic Keratosis emerging therapies
• Actinic Keratosis Market Dynamics: Actinic Keratosis market drivers and Actinic Keratosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Actinic Keratosis Unmet Needs, KOL's views, Analyst's views, Actinic Keratosis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.